<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04913727</url>
  </required_header>
  <id_info>
    <org_study_id>2021-00704</org_study_id>
    <nct_id>NCT04913727</nct_id>
  </id_info>
  <brief_title>Prediction of Reverse Remodeling and Outcome in Patients With Severe Secondary Mitral Valve Regurgitation Undergoing Transcatheter Edge-to-edge Mitral Valve Repair</brief_title>
  <acronym>PRE-MITRA</acronym>
  <official_title>Prediction of Reverse Remodeling and Outcome in Patients With Severe Secondary Mitral Valve Regurgitation Undergoing Transcatheter Edge-to-edge Mitral Valve Repair</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardiocentro Ticino</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Triemli Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators' hypothesis is that CMR tissue characterization and myocardial function&#xD;
      analysis acquired by CMR feature tracking technique predict reverse remodeling in patients&#xD;
      with severe secondary mitral regurgitation (MR) undergoing transcatheter mitral edge-to-edge&#xD;
      repair.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diametrically opposed results of the COAPT- and the MITRA-FR trial have demonstrated the need&#xD;
      for additional evidence in the field of transcatheter mitral edge-to-edge repair. Reverse&#xD;
      left ventricular remodeling after treatment of severe secondary mitral regurgitation can&#xD;
      indicate treatment response and is associated with positive outcomes.&#xD;
&#xD;
      However, so far it is reverse remodeling, respectively treatment response is difficult to&#xD;
      predict, which complicates patient selection for mitral edge-to-edge repair. Previous studies&#xD;
      have shown, that focal (late gadolinium enhancement (LGE)) but not diffuse myocardial&#xD;
      fibrosis (T1 mapping and extracellular volume fraction (ECV)) burden quantification using CMR&#xD;
      predicts reverse left ventricular remodeling following cardiac resynchronization therapy in&#xD;
      patients with heart failure with reduced ejection fraction (HFrEF). On the other hand,&#xD;
      myocardial T1 mapping was predictive for beneficial left ventricular remodeling after&#xD;
      long-term heart failure therapy. Furthermore, in patients with HFrEF, LGE is associated with&#xD;
      clinical outcome and an incremental predictive value to left ventricular dimensions and&#xD;
      function. However, as only 1/3 of HFrEF patients show LGE, subtle fibrosis might be missed.&#xD;
      Recently the investigators have shown that different novel fibrosis detection techniques&#xD;
      (naive T1 mapping, mean ECV and λGd being the delta of pre- and post T1 mapping and ECV&#xD;
      calculation) all demonstrated strong association with outcome in patients with heart failure.&#xD;
&#xD;
      The investigators' hypothesis is that these markers (CMR tissue characterization and&#xD;
      myocardial function analysis acquired by a CMR feature tracking) might also be helpful in&#xD;
      predicting reverse remodeling after transcatheter mitral edge-to-edge repair. This project&#xD;
      might help to understand the pathophysiology of the disease in patients with secondary mitral&#xD;
      regurgitation, improve risk stratification in this clinical setting, and optimize selection&#xD;
      of patients who benefit from transcatheter mitral edge-to-edge repair.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients with reverse remodeling after 12 months</measure>
    <time_frame>12 months after mitral edge-to-edge repair</time_frame>
    <description>Defined as ≥10% reduction in left ventricular end-diastolic volume in patients with successful MR reduction to grade 2+ or less 12 months after mitral edge-to-edge repair assessed by echocardiography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with procedural and device success</measure>
    <time_frame>24 months after mitral edge-to-edge repair</time_frame>
    <description>Procedural and device success as defined according to the criteria of the Mitral Valve Academic Research Consortium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with reverse remodeling after 6 and 24 months</measure>
    <time_frame>6 and 24 months after mitral edge-to-edge repair</time_frame>
    <description>Reverse remodeling at 6 and 24 months, defined according to previously mentioned criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of left ventricular sphericity index</measure>
    <time_frame>6, 12 and 24 months after mitral edge-to-edge repair</time_frame>
    <description>Echocardiographic assessment of LV sphericity index measured using the LV short/long axis dimension ratio in the end-diastolic four-chamber apical view.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NT-proBNP levels</measure>
    <time_frame>6, 12 and 24 months after mitral edge-to-edge repair</time_frame>
    <description>Change in NT-proBNP levels as an indirect sign of changes in left ventricular filling pressure, fibrosis and reverse remodeling will be measured in clinically indicated follow-ups at different time points after the intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause death</measure>
    <time_frame>6, 12 and 24 months after mitral edge-to-edge repair</time_frame>
    <description>Occurence of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>6, 12 and 24 months after mitral edge-to-edge repair</time_frame>
    <description>Occurence of death from cardiovascular reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with heart-failure related hospitalization</measure>
    <time_frame>6, 12 and 24 months after mitral edge-to-edge repair</time_frame>
    <description>Hospitalizations for heart failure within the observation time will be systematically recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NYHA class</measure>
    <time_frame>6, 12 and 24 months after mitral edge-to-edge repair</time_frame>
    <description>Change in NYHA class ≥ +/- 1 compared to baseline NYHA-class before mitral edge-to-edge repair.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in myocardial strain</measure>
    <time_frame>Within 24 months after mitral edge-to-edge repair</time_frame>
    <description>Clinically indicated follow-up imaging (CMR) will be analyzed by CMR feature tracking</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular ejection fraction</measure>
    <time_frame>6, 12 and 24 months after mitral edge-to-edge repair</time_frame>
    <description>Echocardiographic assessment of left ventricular ejection fraction measured according to biplane Simpson disk summation method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Severe Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing transcatheter mitral edge-to-edge repair in this single-arm study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac magnetic resonance imaging before the procedure</intervention_name>
    <description>CMR image acquisition with previously mentioned analysis</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transcatheter mitral edge-to-edge repair.</intervention_name>
    <description>Included patients will undergo Transcatheter mitral edge-to-edge repair.</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with severe secondary MR characterized, according to the European guidelines&#xD;
             and recommendations, by a regurgitant volume ≥30 mL/beat or an effective regurgitant&#xD;
             orifice ≥20 mm².&#xD;
&#xD;
          -  Symptomatic patients with New York Heart Association Class ≥II.&#xD;
&#xD;
          -  Left ventricular ejection fraction between 15% and 50%.&#xD;
&#xD;
          -  Optimal standard of care therapy for heart failure according to investigator.&#xD;
&#xD;
          -  Not eligible for a mitral surgery intervention according to the Heart Team.&#xD;
&#xD;
          -  Patients who have the ability to understand the requirements of the study and provide&#xD;
             written consent/assent to participate and agree to abide by the study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants younger than 18 years&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Severe impaired renal function (GFR &lt; 15 ml/min)&#xD;
&#xD;
          -  Patients with untreated severe concomitant valve disease (e.g. severe tricuspid valve&#xD;
             regurgitation, aortic stenosis)&#xD;
&#xD;
          -  The patient has a medical condition, serious concurrent illness, or extenuating&#xD;
             circumstance that would significantly decrease study compliance, including all&#xD;
             prescribed follow-up&#xD;
&#xD;
          -  The patient has contraindications to CMR, including: Implanted non-CMR conditional&#xD;
             metallic implants, pacemaker, intracardiac defibrillator, neurostimulator, epicardial&#xD;
             pacemaker leads, or any abandoned leads, ferromagnetic aneurysm clip, ferromagnetic&#xD;
             halo device, cochlear implants, implanted infusion pumps or severe claustrophobia&#xD;
&#xD;
          -  The patient is clinically unstable or has stage D congestive heart failure or&#xD;
             inability to lay flat for 60 minutes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph MD Gräni, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, University Hospital Bern, Inselspital, Bern</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christoph MD Gräni, PHD</last_name>
    <phone>+41 31 632 4508</phone>
    <email>christoph.graeni@insel.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Cardiology, University Hospital Bern, Inselspital, Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Gräni, Prof</last_name>
      <phone>+41316324508</phone>
      <email>christoph.graeni@insel.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, Whisenant B, Grayburn PA, Rinaldi M, Kapadia SR, Rajagopal V, Sarembock IJ, Brieke A, Marx SO, Cohen DJ, Weissman NJ, Mack MJ; COAPT Investigators. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med. 2018 Dec 13;379(24):2307-2318. doi: 10.1056/NEJMoa1806640. Epub 2018 Sep 23.</citation>
    <PMID>30280640</PMID>
  </results_reference>
  <results_reference>
    <citation>Obadia JF, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, Lefèvre T, Piot C, Rouleau F, Carrié D, Nejjari M, Ohlmann P, Leclercq F, Saint Etienne C, Teiger E, Leroux L, Karam N, Michel N, Gilard M, Donal E, Trochu JN, Cormier B, Armoiry X, Boutitie F, Maucort-Boulch D, Barnel C, Samson G, Guerin P, Vahanian A, Mewton N; MITRA-FR Investigators. Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. N Engl J Med. 2018 Dec 13;379(24):2297-2306. doi: 10.1056/NEJMoa1805374. Epub 2018 Aug 27.</citation>
    <PMID>30145927</PMID>
  </results_reference>
  <results_reference>
    <citation>Praz F, Grasso C, Taramasso M, Baumbach A, Piazza N, Tamburino C, Windecker S, Maisano F, Prendergast B. Mitral regurgitation in heart failure: time for a rethink. Eur Heart J. 2019 Jul 14;40(27):2189-2193. doi: 10.1093/eurheartj/ehz222.</citation>
    <PMID>31005977</PMID>
  </results_reference>
  <results_reference>
    <citation>Gräni C, Eichhorn C, Bière L, Murthy VL, Agarwal V, Kaneko K, Cuddy S, Aghayev A, Steigner M, Blankstein R, Jerosch-Herold M, Kwong RY. Prognostic Value of Cardiac Magnetic Resonance Tissue Characterization in Risk Stratifying Patients With Suspected Myocarditis. J Am Coll Cardiol. 2017 Oct 17;70(16):1964-1976. doi: 10.1016/j.jacc.2017.08.050. Erratum in: J Am Coll Cardiol. 2017 Nov 28;70(21):2736.</citation>
    <PMID>29025553</PMID>
  </results_reference>
  <results_reference>
    <citation>Gräni C, Bière L, Eichhorn C, Kaneko K, Agarwal V, Aghayev A, Steigner M, Blankstein R, Jerosch-Herold M, Kwong RY. Incremental value of extracellular volume assessment by cardiovascular magnetic resonance imaging in risk stratifying patients with suspected myocarditis. Int J Cardiovasc Imaging. 2019 Jun;35(6):1067-1078. doi: 10.1007/s10554-019-01552-6. Epub 2019 Feb 12.</citation>
    <PMID>30756221</PMID>
  </results_reference>
  <results_reference>
    <citation>Gräni C, Eichhorn C, Bière L, Kaneko K, Murthy VL, Agarwal V, Aghayev A, Steigner M, Blankstein R, Jerosch-Herold M, Kwong RY. Comparison of myocardial fibrosis quantification methods by cardiovascular magnetic resonance imaging for risk stratification of patients with suspected myocarditis. J Cardiovasc Magn Reson. 2019 Feb 28;21(1):14. doi: 10.1186/s12968-019-0520-0.</citation>
    <PMID>30813942</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac magnet resonance (CMR)</keyword>
  <keyword>Mitral Regurgitation</keyword>
  <keyword>Transcatheter mitral edge-to-edge repair</keyword>
  <keyword>MitraClip</keyword>
  <keyword>CMR feature tracking</keyword>
  <keyword>Parametric mapping</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

